# Beijing Shenzhou Cell Biotechnology Group Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-shenzhou-cell-biotechnology-group-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.sinocelltech.com
- Total disclosed funding: $29M
- Latest round: Series A (May 1, 2017)
- Investors on record: 1

## About

Beijing Shenzhou Cell Biotechnology Group Co., Ltd. specializes in advanced cellular therapies, providing innovative solutions to enhance immune response and combat diseases such as cancer and autoimmune disorders.Founded in 2007 in Beijing, China, Beijing Shenzhou Cell Biotechnology Group Co., Ltd. focuses on developing advanced cell-based treatments. The company went public in June 2020, raising CNY 1.280 mn in its IPO, which represents the total amount raised to date. Liangzhi Xie is both the Founder and CEO, leading the company through its strategic initiatives.Beijing Shenzhou Cell Biotechnology Group Co., Ltd. specializes in advanced cellular therapies, focusing on innovative solutions for various medical conditions. Their core product offerings include a range of cell-based treatments designed to enhance immune response and combat diseases such as cancer and autoimmune disorders. The company serves a diverse client base, including hospitals, research institutions, and healthcare providers, primarily in the Asia-Pacific region, with particular emphasis on markets such as China, Japan, and South Korea. The end users of these services primarily include patients undergoing treatment for chronic illnesses, highlighting the company's commitment to addressing significant healthcare challenges through its specialized products.The revenue structure of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. is built around strategic partnerships and direct business transactions with healthcare providers and institutions. Their business model incorporates B2B collaborations, allowing for integrated solutions that enhance patient care and treatment efficacy. Transactions typically involve long-term contracts or agreements that facilitate access to their flagship cell therapies, which may be offered at tiered pricing based on treatment complexity and patient needs. These arrangements ensure a steady revenue stream as healthcare providers adopt their innovative solutions for patient care. Additionally, the company may engage in collaborative research initiatives that further enhance their service offerings and align with evolving medical standards.Beijing Shenzhou Cell Biotechnology Group Co., Ltd. plans to leverage the proceeds from its IPO in June 2020 to expand its product portfolio and geographic reach. The company is designing new cell-based therapies aimed at improving treatment efficacy for autoimmune diseases, with launches expected in the coming years. Additionally, they aim to penetrate new markets in Southeast Asia, particularly targeting Indonesia and Vietnam by 2023, to increase their market footprint and enhance their service offerings.

## Funding rounds

- Series A, May 1, 2017, $29M — Qiming Venture Partners

## Investors

- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A